LUND, Sweden, Sept. 29, 2020 /PRNewswire/ -- Immunovia, a
diagnostic company that develops highly accurate blood tests for
the early detection of cancer and autoimmune diseases, today
announced positive results from the verification study and will now
commence the validation study, the last step towards the launch of
IMMray™ PanCan-d. The verification study
analysis shows results in line with the previous commercial test
model study (CTMS), which paves the way for the final blinded
validation study.
"We are very pleased with the results of the verification study
and are now commencing the preparation for the validation process,
while finishing up some bioinformatics for all subgroups of
samples," said Mats Grahn, CEO.
"These results will be made public as soon as the study is
completed in all its details. We remain fully committed to the
launch of IMMray™ PanCan-d and are now only one step away from the
Q4 start sales of IMMray™ PanCan-d."
About the Verification Study
The study was performed in order to verify the IMMray™ PanCan-d
commercial biomarker signature using known samples and to further
validate its accuracy in differentiating PDAC (pancreatic ductal
adenocarcinoma) stages I through IV vs. controls that best mirror
the clinical, commercial setting situation (i.e. patients with
non-specific but concerning symptoms). All the samples were freshly
collected through our Key Opinion Leaders (KOL) at pancreatic
diseases reference sites in USA and Europe. The verification study precedes the
final blinded validation study required for sales start.
This is information that Immunovia is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was
submitted for publication, through the agency of the contact person
set out above, at 08:30 CET on
September 29, 2020.
For more information, please contact:
Julie Silber,
Director of Investor Relations, Immunovia
Email: julie.silber@immunovia.com
Tel: +46 7 93 486 277
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is
currently in the final validation for sales start Q4
2020. When validated, IMMray™ PanCan-d will be the first
blood-based test for early diagnosis of pancreatic cancer on the
market, with a potential to significantly improve patient survival
and outcome.
Immunovia Dx Laboratories located in Marlborough, Massachusetts, USA and
Lund, Sweden will provide
laboratory testing services in two accredited reference
laboratories.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/immunovia-announces-positive-results-from-the-immray--pancan-d-verification-study,c3204442
The following files are available for download:
https://mb.cision.com/Main/13121/3204442/1311973.pdf
|
Release
|
View original
content:http://www.prnewswire.com/news-releases/immunovia-announces-positive-results-from-the-immray-pancan-d-verification-study-301139551.html
SOURCE Immunovia AB